{"id":193673,"date":"2017-05-18T14:31:22","date_gmt":"2017-05-18T18:31:22","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/regulatory-recon-fda-expands-use-of-cf-drug-asco-abstracts-released-18-may-2017-regulatory-focus\/"},"modified":"2017-05-18T14:31:22","modified_gmt":"2017-05-18T18:31:22","slug":"regulatory-recon-fda-expands-use-of-cf-drug-asco-abstracts-released-18-may-2017-regulatory-focus","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/cf\/regulatory-recon-fda-expands-use-of-cf-drug-asco-abstracts-released-18-may-2017-regulatory-focus\/","title":{"rendered":"Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) &#8211; Regulatory Focus"},"content":{"rendered":"<p><p>Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts    Released (18 May 2017)        Posted 18 May 2017 By Zachary    Brennan    <\/p>\n<\/p>\n<p>      Welcome to Regulatory Recon, a      daily regulatory news and intelligence briefing.    <\/p>\n<p>      In Focus:      US    <\/p>\n<p>      In Focus:      International    <\/p>\n<p>      Pharmaceuticals and      Biotechnology    <\/p>\n<p>      Pharmaceuticals and      Biotechnology: Study Results, Filings and      Designations    <\/p>\n<p>      Medical      Devices    <\/p>\n<p>      US: Assorted and      Government    <\/p>\n<p>      Upcoming Meetings and      Events    <\/p>\n<p>      General Health and Other      Interesting Articles    <\/p>\n<p>      Regulatory Reconnaissance is      our daily intelligence briefing for the regulatory affairs      space, bringing you the top regulatory news stories from      around the globe. Each weekday morning, we aim to bring you      the latest highlights of new approvals, meetings, legal and      political developments, regulations and guidance, and the      latest trends with the potential to impact regulatory affairs      professionals and the industry in which they      work.    <\/p>\n<p>      Need to contact the editor of      Regulatory Reconnaissance? Send him an email      <a href=\"mailto:atnews@raps.org\">atnews@raps.org<\/a>.      A story's inclusion in Regulatory Reconnaissance does not      imply endorsement by Regulatory Focus or RAPS.    <\/p>\n<p>      Share this article:    <\/p>\n<p>      Categories:      Biologics and      biotechnology, Drugs, Medical Devices,      US, Canada, Europe, FDA, Health Canada    <\/p>\n<p>      Tags: ASCO, Regulatory      Reconnaissance, Regulatory,      Links, News, Regulatory      News, Regulatory      Intelligence, FDA News, EMA News    <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"http:\/\/raps.org\/Regulatory-Focus\/News\/2017\/05\/18\/27585\/Regulatory-Recon-FDA-Expands-Use-of-CF-Drug;-ASCO-Abstracts-Released-18-May-2017\/\" title=\"Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) - Regulatory Focus\">Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) - Regulatory Focus<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Regulatory Recon: FDA Expands Use of CF Drug; ASCO Abstracts Released (18 May 2017) Posted 18 May 2017 By Zachary Brennan Welcome to Regulatory Recon, a daily regulatory news and intelligence briefing. In Focus: US In Focus: International Pharmaceuticals and Biotechnology Pharmaceuticals and Biotechnology: Study Results, Filings and Designations Medical Devices US: Assorted and Government Upcoming Meetings and Events General Health and Other Interesting Articles Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/cf\/regulatory-recon-fda-expands-use-of-cf-drug-asco-abstracts-released-18-may-2017-regulatory-focus\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[187753],"tags":[],"class_list":["post-193673","post","type-post","status-publish","format-standard","hentry","category-cf"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/193673"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=193673"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/193673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=193673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=193673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=193673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}